|Awarded On||February 21, 2019|
|Title||A Novel Therapy Targeting Prostate Cancer–Induced Aberrant Bone Formation|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Sue-Hwa Lin|
|Cancer Sites||Bone, Prostate|
*Pending contract negotiation
Development of metastasis in bone is the lethal progression of prostate cancer (PCa). Most approved therapeutic agents only modestly improve patient survival. PCa bone metastasis is unique in that the bone lesions tend to be bone forming rather than bone lysing, which occurs in other cancers. PCa-induced aberrant bone supports cancer cells’ survival and resistance to chemotherapy. Thus, traditional cancer therapy that targets tumor cells has failed to impact patients’ survival. Our proposed studies will target the tumor-induced aberrant bone formation as an integral part of treatment for bone metastasis. Our studies on the mechanism of PCa-induced aberrant bone formation revealed a surpri...